Results 51 to 60 of about 201 (100)
POSSIBILITIES OF PREVENTION AND TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTIONS INCLUDING NEW DRUGS AND COMPOUNDS WITH POTENTIAL APPLICATION [PDF]
Postępy Mikrobiologii, 2019 Anna Majewska +4 more
doaj +1 more source
Letermovir in paediatric HSCT recipients
Journal of Antimicrobial Chemotherapy, 2019 Volker, Strenger +7 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Letermovir for the management of cytomegalovirus infection
Expert Opinion on Investigational Drugs, 2016Cytomegalovirus (CMV) is a major cause of morbidity and mortality in immunocompromised patients. Available antivirals are fraught with adverse effects and risk for the development of CMV resistance. Letermovir is a novel antiviral in the late stages of drug development for the treatment and prevention of CMV. Areas covered: A MEDLINE search of the MeSH
Lyndsey J. Bowman +2 more
openaire +2 more sources
Letermovir: First Global Approval
Drugs, 2017Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive ...
openaire +2 more sources